Routine immunization profile
Israel

World Health Organization
REGIONAL OFFICE FOR Europe

Progress towards achieving European Vaccine Action Plan goals, 2017

Goal	Indicator	Status	Goal	Indicator	Status
1	Sustain polio-free status[a] *(Current risk)*	Yes *(Low)*	4	Meets vaccination coverage targets *DTP3 national immunization coverage ≥95%*[d] *≥90% DTP3 coverage achieved in ≥90% of districts*[e]	Yes *Yes* *Yes*
2	Measles elimination status[b]	Eliminated	5	Make evidence-based decisions about introduction of new vaccines*[e] *NITAG made a recommendation about PCV* *NITAG made a recommendation about RV* *NITAG made a recommendation about HPV*	Yes *Yes* *Yes* *Yes*
	Rubella elimination status[b]	Eliminated			
3	Control hepatitis B infection[c]	Validation pending	6	Achieve financial sustainability of the national immunization programme**[c]	Yes

*New vaccines introduced or not introduced based on NITAG evidence-based recommendations
**Country self-sufficient for procuring routine vaccines

Demographic, income and health expenditure summary, 2017

Total Population[f]	8 321 570
Live births	165 618
Surviving infants	165 152
<5 years	841 581
<15 years	2 318 579
Neonatal mortality rate (per 1000 live births)[f]	2
Infant mortality rate (per 1000 live births)[f]	2.9
Number of districts[e]	15
GNI (per capita, in USD)[g]	37 400
Health spending as % of total government expenditure[g]	ND

Immunization schedule, 2017[e]

Birth	HepB_Pediatric
1M	HepB_Pediatric
2M	DTaPHibIPV, PCV, Rotavirus
4M	DTaPHibIPV, PCV, Rotavirus
6M	DTaPHibIPV, HepB_Pediatric, OPV, Rotavirus
12M	DTaPHibIPV, MMRV, PCV
18M	HepA_Pediatric, OPV
24M	HepA_Pediatric
6Y	MMRV
7Y	TdaPIPV
13Y	HPV*, Tdap

*Second dose +6M

Routine immunization profile
Israel

World Health Organization
REGIONAL OFFICE FOR Europe

Vaccine coverage estimates, 2013-2017[d]

	2013	2014	2015	2016	2017
BCG	NR	NR	NR	NR	NR
HepB-BD	97	97	96	95	95
DTP1	96	95	95	94	99
DTP3	96	95	95	94	98
HepB3	97	97	96	95	97
Hib3	96	95	95	94	98
Pol3	96	95	95	94	98
PCV3	94	94	94	93	94
Rotac	80	81	80	81	81
RCV1	98	97	98	97	98
MCV1	98	97	98	97	98
MCV2	95	96	97	97	96

100 50 0 ND NR

DTP3 reported coverage by subnational area†, 2017[e]



MCV1 reported coverage by subnational area†, 2017[e]



MCV2 reported coverage by subnational area†, 2017[e]



Number of reported cases of vaccine-preventable diseases, 2013-2017[e]

	2013	2014	2015	2016	2017
Measles	50	6	80	8	42
Mumps	51	140	47	51	343
Rubella	1	0	1	1	1
Congenital rubella syndrome	0	0	0	0	0
Diphtheria	0	0	0	0	0
Tetanus	1	0	0	2	0
Pertussis	1394	1509	5338	1143	467
Hepatitis A	59	52	51	50	72
Varicella	1473	1462	1749	2470	2347

Surveillance with laboratory confirmation of cases, 2017[e]

Measles	Yes
Rubella	Yes
Congenital rubella syndrome	Yes
Rotavirus	No
Invasive meningococcal disease	Yes
Invasive pneumococcal disease	Yes
Invasive *Haemophilus influenzae* disease	Yes

Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive *Haemophilus influenzae* disease.

Routine immunization profile
Israel

World Health Organization
REGIONAL OFFICE FOR Europe

Number of reported measles, mumps and rubella cases[e] and MCV coverage estimates[d], 2013-2017



Number of reported diphtheria, tetanus and pertussis cases[e] and DTP3 coverage estimates[d], 2013-2017



Percentage of districts by DTP3 reported coverage[e], 2013-2017



DTP1-DTP3 dropout rate, 2013-2017[d]



Note: Dropout rate is calculated using WUENIC

Immunization system characteristics, 2017

Sustained access to WHO accredited polio, measles, and rubella laboratories[h]	Yes
NITAG in place that meets six WHO criteria[e]	Yes
National system in place to monitor AEFIs[e]	Yes
Communication plan in place to respond to vaccine safety-related events[e]	ND
Vaccine hesitancy assessment performed within last 5 years [e,i]	Yes
Mandatory proof of immunization at school entry[e]	No

Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest

Routine immunization profile
Israel

World Health Organization
REGIONAL OFFICE FOR Europe

Vaccine stockouts by administrative level[e], 2013-2017

	2013	2014	2015	2016	2017
BCG	No	No	No	No	No
DTP	No	No	No	No	No
HepB	No	No	No	No	No
Hib	No	No	No	No	No
Pneumo	No	No	No	No	No
Rota	No	No	No	No	No
OPV	No	No	No	No	No
IPV	No	No	No	No	No
Measles	No	No	No	No	No
HPV	*	*	*	No	No
TT	No	No	No	No	No



*Data on HPV stockouts have only been collected in JRF since 2016

Abbreviations

AEFI	Adverse event following immunization
BCG	Bacille Calmette-Guerin vaccine for tuberculosis
CRS	congenital Rubella Syndrome
DT	diptheria-tetanus-containing vaccine
DTP	diptheria-tetanus-pertussis-containing vaccine
DTP1	diphtheria-tetanus-pertussis-containing vaccine, first dose
DTP3	diphtheria-tetanus-pertussis-containing vaccine, third dose
GNI	Gross national income
HepB	hepatitis B
HepB3	hepatitis B vaccine, third dose
HepB-BD	hepatitis B vaccine, birth dose
Hib	Haemophilus influenzae type b
Hib3	Haemophilus influenzae type b vaccine, third dose
HPV	human papillomavirus
IPV	inactivated polio vaccine
MCV	measles-containing vaccine
MCV1	measles-mumps-rubella vaccine, first dose
MCV2	measles-mumps-rubella vaccine, second dose
MMR	measles-mumps-rubella vaccine
ND	Data not available
NITAG	National Immunization Technical Advisory Group
NR	Not relevant as vaccine not included in immunization schedule
OPV	oral polio vaccine
PCV	pneumococcal conjugate vaccine
PCV3	pneumococcal conjugate vaccine , third dose
Pol3	polio-containing vaccine, third dose
RCV1	rubella-containing vaccine, first dose
Rotac	rotavirus vaccine-complete series
Td	tetanus-diphtheria-containing vaccine
TT	tetanus toxoid vaccine
W,M,Y	Weeks, Months, Years

Data sources

a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC
b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC
c European Vaccine Action Plan 2015-2020 Midterm report
d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): (http://www.who.int/immunization/monitoring_surveillance/data/en/)
e WHO/UNICEF Joint Reporting Form on immunization (JRF)
f World Population Prospects: The 2017 Revision, New York, United Nations
g World Bank, World Development Indicators
h Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network
i Communication with the country

Map disclaimer

† The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.